Geode Capital Management
AYTU icon

Geode Capital Management’s AYTU BioPharma AYTU Stock Holding History

Geode Capital Management’s Portfolio AYTU Stock Details AYTU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$253K Buy
92,636
+18,539
+25% +$47.4K ﹤0.01% 3842
2025
Q4 		$193K Buy
74,097
+3,091
+4% +$6.93K ﹤0.01% 3921
2025
Q3 		$134K Buy
71,006
+17,137
+32% +$39.6K ﹤0.01% 4051
2025
Q2 		$117K Sell
53,869
-75
-0.1% -$116 ﹤0.01% 4022
2025
Q1 		$64.8K Buy
53,944
+11,211
+26% +$16.3K ﹤0.01% 4144
2024
Q4 		$71.4K Sell
42,733
-2,369
-5% -$4.33K ﹤0.01% 4178
2024
Q3 		$106K Buy
45,102
+9,183
+26% +$23.8K ﹤0.01% 4089
2024
Q2 		$105K Buy
35,919
+1,356
+4% +$4.09K ﹤0.01% 4127
2024
Q1 		$105K Buy
34,563
+1,517
+5% +$4.34K ﹤0.01% 4148
2023
Q4 		$93.9K Buy
33,046
+16,511
+100% +$45.5K ﹤0.01% 4203
2023
Q3 		$44.7K Buy
16,535
+4,639
+39% +$8.12K ﹤0.01% 4445
2023
Q2 		$19K Sell
11,896
-143
-1% -$281 ﹤0.01% 4661
2023
Q1 		$27.1K Sell
12,039
-2
-0% -$6 ﹤0.01% 4650
2022
Q4 		$46K Sell
12,041
-37
-0.3% -$139 ﹤0.01% 4609
2022
Q3 		$44K Sell
12,078
-529
-4% -$4.01K ﹤0.01% 4789
2022
Q2 		$173K Sell
12,607
-345
-3% -$4.42K ﹤0.01% 4359
2022
Q1 		$279K Buy
12,952
+80
+0.6% +$1.99K ﹤0.01% 4213
2021
Q4 		$347K Hold
12,872
– – ﹤0.01% 4226
2021
Q3 		$741K Buy
12,872
+1,800
+16% +$135K ﹤0.01% 3836
2021
Q2 		$1.11M Sell
11,072
-7,007
-39% -$822K ﹤0.01% 3538
2021
Q1 		$2.75M Buy
18,079
+12,910
+250% +$2.05M ﹤0.01% 3104
2020
Q4 		$618K Buy
5,169
+1,885
+57% +$343K ﹤0.01% 3526
2020
Q3 		$781K Buy
3,284
+1,536
+88% +$395K ﹤0.01% 3295
2020
Q2 		$496K Buy
1,748
+1,421
+435% +$430K ﹤0.01% 3380
2020
Q1 		$98K Hold
327
– – ﹤0.01% 3773
2019
Q4 		$63K Hold
327
– – ﹤0.01% 4051
2019
Q3 		$79K Hold
327
– – ﹤0.01% 3996
2019
Q2 		$123K Buy
327
+54
+20% +$20.6K ﹤0.01% 3912
2019
Q1 		$91K Hold
273
– – ﹤0.01% 3916
2018
Q4 		$43K Buy
+273
New +$60.1K ﹤0.01% 4015

Other funds holding AYTU

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
DP
Diadema Partners Morristown, New Jersey $588M AUM 182.75% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
CAM
Crown Advisors Management Larkspur, California $151M AUM 73.11% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
PAP
Persistent Asset Partners Hong Kong $268M AUM 158.98% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Geode Capital Management's AYTU Position: Q1 2026 in Review

Geode Capital Management increased its AYTU BioPharma (AYTU) stake by 25% in Q1 2026, buying an estimated $47.4K and bringing the position to 92,636 shares worth $253K. The position accounts for ﹤0.01% of the portfolio, ranked #3842.

Geode Capital Management first reported a position in AYTU in Q4 2018 and has held it in 30 quarters since. The position peaked at $2.75M in Q1 2021. 37 funds tracked by Wall St. Rank hold AYTU as of Q1 2026.

  • Geode Capital Management held 92,636 shares of AYTU BioPharma worth $253K as of Q1 2026.
  • Geode Capital Management bought 18,539 AYTU BioPharma shares in Q1 2026, an estimated $47.4K.
  • AYTU BioPharma made up ﹤0.01% of Geode Capital Management's portfolio in Q1 2026, its #3842 holding.
  • Geode Capital Management first reported a position in AYTU BioPharma in Q4 2018 and has held it in 30 quarters since.
  • Geode Capital Management's AYTU BioPharma position peaked at $2.75M in Q1 2021.
  • 37 funds tracked by Wall St. Rank held AYTU BioPharma as of Q1 2026.

Based on Geode Capital Management's 13F filing for Q1 2026, filed 15 May 2026.